Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech? We
Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy? We cover all that and more this week on “The Readout LOUD,”
What do CEOs owe the world? Did Humira break the system? And can you CRISPR a fetus? We cover all that and more this week
Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine? We cover all that and more this
Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin? We cover all that and more this week
What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator? We cover all that and more this week
Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid? We cover all that and more this
Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024? We cover all that and
Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus? We cover all
What does it mean to a bad CEO? Can biotech endure another election year? And can you go to too many J.P. Morgan parties? We